Welcome to our dedicated page for Silexion Therapeutics news (Ticker: SLXN), a resource for investors and traders seeking the latest updates and insights on Silexion Therapeutics stock.
Silexion Therapeutics Corp (NASDAQ: SLXN) is a clinical-stage biotechnology company developing RNA interference (RNAi) therapies for KRAS-driven cancers, with a lead focus on locally advanced pancreatic cancer. The news flow around Silexion centers on its progress with SIL204, a next-generation siRNA therapy designed to silence mutated KRAS oncogenes that drive aggressive solid tumors.
Readers following SLXN news can expect updates on preclinical data, regulatory milestones, and clinical trial preparations. Recent press releases have highlighted new human cancer cell line results demonstrating high inhibition across multiple KRAS mutations and organ sites, including pancreatic, colorectal, lung, and gastric cancer models. The company has also reported biodistribution and efficacy data in metastatic pancreatic cancer models, as well as completion of two-species toxicology studies that it states confirmed no systemic organ toxicity.
Another key theme in Silexion’s news is its regulatory and clinical development pathway for SIL204. The company has announced formal written Scientific Advice from Germany’s Federal Institute for Drugs and Medical Devices (BfArM) on the design of its planned Phase 2/3 trial in locally advanced pancreatic cancer, submission of a clinical trial application in Israel, and plans for additional submissions in Europe and the United States. Operational updates include selection of a contract research organization, manufacturing collaborations, and preparations for trial initiation.
In addition, Silexion’s news releases cover financing transactions, capital-raising activities, and Nasdaq listing matters, such as regaining compliance with minimum bid price and shareholders’ equity requirements. Investors and observers can use this news page to review company communications on scientific results, regulatory interactions, business developments, and conference presentations related to Silexion’s KRAS-focused RNAi oncology programs.
Silexion Therapeutics (NASDAQ: SLXN) is approaching a important milestone with upcoming orthotopic pancreatic cancer model data for its SIL-204 therapy. The study evaluates the treatment's effectiveness in reducing primary tumor growth and inhibiting metastatic spread in pancreatic cancer models.
Previous studies have shown promising results, with SIL-204 demonstrating a 50% reduction in tumor growth and complete necrosis in half of treated tumors. The therapy has maintained therapeutic levels for over 56 days from a single dose. The RNAi-based approach targets multiple KRAS mutations (G12D, G12V, G12R, Q61H, and G13D), potentially offering broader therapeutic benefits than existing treatments.
The data readout, expected in March 2025, could validate systemic efficacy against metastatic disease for the first time. Maxim Group maintains a $9 price target and strong buy rating on SLXN, citing the company's clinical trajectory and RNAi platform validation.
Silexion Therapeutics (NASDAQ: SLXN) has completed its initial study evaluating SIL-204 in orthotopic pancreatic cancer models, marking the first systematic evaluation of this RNA interference therapy administered subcutaneously in clinically relevant models.
The study assessed two critical aspects of SIL-204's potential:
- Ability to reduce primary tumor growth when administered systemically
- Capacity to reduce metastatic spread from orthotopic tumors to secondary organs
Unlike standard subcutaneous xenograft models, the orthotopic models used in this study better represent the complex microenvironment of pancreatic tumors and their metastatic behavior by allowing tumors to develop in their native environment.
Data analysis is currently underway, with initial results expected to be reported in March 2025. These findings will inform Silexion's development strategy for SIL-204 in addressing both localized and metastatic pancreatic cancer.
Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech focused on RNAi therapies for KRAS-driven cancers, has announced agreements for the immediate exercise of outstanding warrants. The exercise involves 2,221,523 ordinary shares at $1.35 per share, expected to generate approximately $3.3 million in gross proceeds.
The company will issue new unregistered warrants to purchase an additional 2,221,523 ordinary shares at $1.50 per share, exercisable immediately upon issuance with a 24-month term. Warrant holders will pay an additional $0.125 per new warrant, contributing $277,690.38 to the gross proceeds. H.C. Wainwright & Co. serves as the exclusive placement agent, and the offering is expected to close around January 30, 2025.
The proceeds will be used as working capital for general corporate purposes. The company will file a registration statement with the SEC for the resale of shares issuable under the new warrants.
Silexion Therapeutics (NASDAQ: SLXN) has reported promising preclinical data for SIL-204, its next-generation siRNA therapeutic candidate targeting KRAS-driven cancers. The key findings demonstrate that systemic administration of SIL-204 effectively reduced tumor growth by ~50% after 30 days, with ~50% of tumors showing complete necrosis in human pancreatic tumor models.
The data revealed that SIL-204 can inhibit multiple oncogenic KRAS mutations (G12D, G12V, G12R, Q61H, and G13D) and maintain effective drug levels in rat plasma and tissues for over 56 days after a single administration. In intratumoral administration tests, SIL-204 microparticles reduced tumor cell numbers by ~3-fold, tumor area by ~1.5-fold, and increased tumor necrosis by ~5-fold after 15 days.
The company is now planning further studies to evaluate SIL-204's impact on metastases and expects to announce an expanded development plan for KRAS-driven cancers.
Silexion Therapeutics (NASDAQ: SLXN) has unveiled promising preclinical data for SIL-204, its next-generation siRNA candidate targeting KRAS-driven cancers. The data demonstrates significant synergy between SIL-204 and first-line chemotherapy agents, including 5-fluorouracil, irinotecan, and gemcitabine.
In human pancreatic tumor cell models with KRAS G12D mutations, SIL-204 enhanced the effectiveness of standard therapies, showing greater reductions in cancer cell confluence compared to chemotherapy alone. This is particularly significant as KRAS mutations are present in over 90% of pancreatic cancer cases.
Building on its first-generation LODER™ platform's success in Phase 2 trials, SIL-204 targets a broader spectrum of KRAS mutations. The company plans to begin toxicology studies soon, with Phase 2/3 trials scheduled for 2026. Additionally, Silexion announced a $5 million public offering to support its research efforts.
Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech focused on RNA interference therapies for KRAS-driven cancers, has announced the pricing of a $5.0 million public offering. The offering consists of 3,703,703 ordinary shares (or equivalents) and warrants to purchase up to 3,703,703 ordinary shares at a combined price of $1.35 per share and accompanying warrant.
The warrants will have an exercise price of $1.35 per share, will be immediately exercisable, and will expire in five years. The offering is expected to close around January 17, 2025, with H.C. Wainwright & Co. acting as exclusive placement agent. The company plans to use the proceeds to advance pre-clinical studies and for general corporate purposes.
Silexion Therapeutics (NASDAQ: SLXN) has announced promising new preclinical results for its second-generation siRNA candidate, SIL-204, showing significant synergistic activity when combined with standard pancreatic cancer chemotherapies. The data demonstrates that SIL-204 enhances the effectiveness of 5-fluorouracil, irinotecan, and gemcitabine in human pancreatic tumor cell lines with KRAS G12D mutations.
The combination of SIL-204 with 5-fluorouracil and irinotecan achieved a significant reduction in cancer cell confluence after three days compared to chemotherapy alone (p 0.0005). These results build upon previous successes with the company's first-generation product, LODER™, which demonstrated improved overall survival in Phase 2 trials.Silexion plans to initiate toxicology studies for SIL-204 in the coming months and advance to Phase 2/3 clinical trials in the first half of 2026, focusing on locally advanced pancreatic cancer (LAPC). The company also plans to begin preclinical studies for SIL-204 in colorectal cancer models.
Silexion Therapeutics (NASDAQ: SLXN) has announced its upcoming presentation at the 2025 ASCO Gastrointestinal Cancers Symposium in San Francisco from January 23-25, 2025. The company will present data on SIL-204, their RNA interference therapy targeting KRAS-driven cancers.
The presentation, titled 'SIL-204 siRNA free and encapsulated in extended release microparticles for the treatment of localized and systemic cancer that harbors a KRAS G12x, Q61H, or G13D mutation,' will be delivered by Mitchell Shirvan, Ph.D. during the Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract session on January 24, 2025, from 11:30 AM to 1:00 PM PST.
The abstract will be published on the symposium's website on January 21, 2025, at 5:00 p.m. ET, and the poster will subsequently be available on Silexion's website under the 'Our Science' section.
Silexion Therapeutics (NASDAQ: SLXN) is advancing precision oncology through its collaboration with Evonik, developing a long-acting PLGA microparticle formulation for SIL-204, its next-generation siRNA candidate targeting KRAS mutations. Preclinical studies demonstrated high efficacy in reducing tumor size in KRAS-mutated pancreatic cancer models.
The company's RNAi approach silences KRAS mutations at the genetic level, targeting a broader range of mutations (pan-G12x and G13D) with potential applications in pancreatic, colorectal, and lung cancers. This advancement comes amid surging oncology M&A activity, exemplified by Pfizer's $43 billion Seagen acquisition and AbbVie's $10.1 billion Immunogen purchase.
The KRAS inhibitor market is projected to grow at 36% CAGR, reaching $10 billion by 2032. Silexion aims to advance SIL-204 into Phase 2/3 trials by 2025-2026.
Silexion Therapeutics (NASDAQ: SLXN) has announced its collaboration with Evonik for developing an advanced siRNA formulation for cancer treatment. The partnership focuses on creating a long-acting siRNA PLGA microparticle formulation for SIL-204, Silexion's next-generation siRNA candidate.
The formulation, utilizing Evonik's proprietary biodegradable RESOMER® technology, has shown high efficacy in preclinical models using mice with human pancreatic tumor cell lines carrying various KRAS mutations. The collaboration aims to enhance cancer treatment through sustained-release RNAi therapy, specifically targeting KRAS mutations, a significant challenge in oncology.